Published in Neurosci Lett on May 08, 2003
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol (2009) 2.68
Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology (2004) 2.23
alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am J Pathol (2004) 1.53
alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathol (2004) 1.43
Clinical, cognitive and anatomical evolution from nonfluent progressive aphasia to corticobasal syndrome: a case report. Neurocase (2004) 1.21
Update on recent molecular and genetic advances in frontotemporal lobar degeneration. J Neuropathol Exp Neurol (2008) 1.08
PRKAR1B mutations are a rare cause of FUS negative neuronal intermediate filament inclusion disease. Brain (2014) 0.97
FUS immunogold labeling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy. J Mol Neurosci (2011) 0.88
The spectrum and severity of FUS-immunoreactive inclusions in the frontal and temporal lobes of ten cases of neuronal intermediate filament inclusion disease. Acta Neuropathol (2010) 0.87
The many ways to frontotemporal degeneration and beyond. Neurol Sci (2007) 0.83
Neuropathological changes in ten cases of neuronal intermediate filament inclusion disease (NIFID): a study using alpha-internexin immunohistochemistry and principal components analysis (PCA). J Neural Transm (Vienna) (2005) 0.81
Optic nerve crush induces spatial and temporal gene expression patterns in retina and optic nerve of BALB/cJ mice. Mol Neurodegener (2014) 0.78
A morphometric study of the spatial patterns of TDP-43 immunoreactive neuronal inclusions in frontotemporal lobar degeneration (FTLD) with progranulin (GRN) mutation. Histol Histopathol (2011) 0.78
Spatial patterns of the pathological changes in neuronal intermediate filament inclusion disease (NIFID): an alpha-internexin immunohistochemical study. J Neural Transm (Vienna) (2006) 0.78
Spatial patterns of FUS-immunoreactive neuronal cytoplasmic inclusions (NCI) in neuronal intermediate filament inclusion disease (NIFID). J Neural Transm (Vienna) (2011) 0.77
Inactivation of CDK/pRb pathway normalizes survival pattern of lymphoblasts expressing the FTLD-progranulin mutation c.709-1G>A. PLoS One (2012) 0.77
Spatial patterns of TDP-43 neuronal cytoplasmic inclusions (NCI) in fifteen cases of frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP). Neurol Sci (2011) 0.76
Specialized roles of neurofilament proteins in synapses: Relevance to neuropsychiatric disorders. Brain Res Bull (2016) 0.75
Fronto-temporal lobar degeneration: neuropathology in 60 cases. J Neural Transm (Vienna) (2011) 0.75
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain (2004) 7.38
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet (2006) 6.52
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol (2006) 4.24
Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet (2005) 4.21
Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol (2006) 4.19
A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol (2011) 4.15
Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A (2002) 4.07
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol (2003) 3.44
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. Neuroimage (2002) 3.06
Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest (2008) 2.91
Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci (2004) 2.84
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66
Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain (2012) 2.65
Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol (2003) 2.61
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis (2006) 2.42
Posterior cortical atrophy. Lancet Neurol (2012) 2.41
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Single-cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene. Ann Neurol (2009) 2.21
Frontotemporal dementia in elderly individuals. Arch Neurol (2012) 2.21
"-but who is that on the other side of you?" Extracampine hallucinations revisited. Lancet (2002) 2.16
A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain (2008) 2.13
Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain (2011) 2.13
Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet (2013) 2.09
Assessing the onset of structural change in familial Alzheimer's disease. Ann Neurol (2003) 2.07
Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia. Arch Neurol (2005) 2.06
Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain (2004) 2.06
Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease. Brain (2013) 2.05
[Of what significance are diseases, intoxication and suicide in fatal traffic accidents?]. Tidsskr Nor Laegeforen (2004) 2.05
Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet (2003) 2.02
Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci U S A (2008) 1.93
Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J Neurochem (2006) 1.91
Life with communication changes in Parkinson's disease. Age Ageing (2006) 1.90
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain (2011) 1.89
Ischemic basis for deep white matter hyperintensities in major depression: a neuropathological study. Arch Gen Psychiatry (2002) 1.88
Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with lewy bodies. Am J Psychiatry (2004) 1.82
Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol (2006) 1.81
Progressive logopenic/phonological aphasia: erosion of the language network. Neuroimage (2009) 1.76
The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology (2013) 1.74
Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree? J Am Geriatr Soc (2008) 1.74
Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler (2010) 1.72
Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat (2007) 1.69
Education, the brain and dementia: neuroprotection or compensation? Brain (2010) 1.68
The natural history of Alzheimer disease: a longitudinal presymptomatic and symptomatic study of a familial cohort. Arch Neurol (2004) 1.67
Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. Neuroimage (2010) 1.62
Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Ann Neurol (2005) 1.62
Volumetric MRI and cognitive measures in Alzheimer disease : comparison of markers of progression. J Neurol (2008) 1.60
Neurofilament inclusion body disease: a new proteinopathy? Brain (2003) 1.59
The impact of pathogenic mitochondrial DNA mutations on substantia nigra neurons. J Neurosci (2013) 1.59
Visual hallucinations in dementia with Lewy bodies: transcranial magnetic stimulation study. Br J Psychiatry (2011) 1.58
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.58
Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol (2003) 1.55
Comparing gray matter loss profiles between dementia with Lewy bodies and Alzheimer's disease using cortical pattern matching: diagnosis and gender effects. Neuroimage (2004) 1.53
alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am J Pathol (2004) 1.53
Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry (2007) 1.52
Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet (2005) 1.51
Differentiating AD from aging using semiautomated measurement of hippocampal atrophy rates. Neuroimage (2004) 1.48
Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol (2006) 1.48
Protective effects of angiopoietin-like 4 on cerebrovascular and functional damages in ischaemic stroke. Eur Heart J (2013) 1.47
The clinical profile of right temporal lobe atrophy. Brain (2009) 1.46
Independent domains of gait in older adults and associated motor and nonmotor attributes: validation of a factor analysis approach. J Gerontol A Biol Sci Med Sci (2012) 1.45
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med (2014) 1.45
Aggressive course of disease in dementia. Alzheimers Dement (2006) 1.44
Global democratic consensus on neuropathological disease criteria. Lancet Neurol (2002) 1.44
alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathol (2004) 1.43
Suspected early dementia. BMJ (2011) 1.41
VBM signatures of abnormal eating behaviours in frontotemporal lobar degeneration. Neuroimage (2007) 1.40